ICN Pharmaceuticals Raises Dividend 1 Cent
Costa Mesa drug maker ICN Pharmaceuticals said Monday its directors boosted the quarterly dividend to 7 cents a share from 6 cents, payable April 28 to shareholders of record April 14.
The company posted a fourth-quarter loss of $218 million as it wrote off a Yugoslavian plant seized by Serbian troops. But other regions are performing well, and the company believes its drug ribavirin has a bright future as a hepatitis treatment. Last year, Schering-Plough Corp. won U.S. approval of a hepatitis treatment that combines ribavirin with Intron A.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
